A randomized, double‐blind, placebo‐controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis
Overview of attention for article published in Muscle & Nerve, April 2013
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (94th percentile)
-
High Attention Score compared to outputs of the same age and source (97th percentile)
Mentioned by
- policy
- 1 policy source
- 1 X user
- patent
- 30 patents
- guideline
- 1 clinical guideline source
Readers on
- mendeley
- 171 Mendeley